Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says
Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase 3 plans for 2027.
Opus Genetics found that their new eye medicine works even at smaller doses, which is good news for safety. When a company shows its medicine is working, people watch to see if the FDA will approve it for real patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.